Total collaboration revenues for 2011 were $164.8 million compared with $44.7 million for 2010. The primary driver for the increase was revenue recognized in conjunction with AVEO’s collaboration agreements with Astellas and Centocor, as well as revenue from OSI primarily related to the exercise of its option to acquire certain rights to our technology platform. These increases were partially offset by the fact that no revenues were earned from Merck as a result of the termination of the companies’ collaboration agreement in December 2010.

Research and development (R&D) expense for 2011 was $101.7 million compared with $86.3 million for 2010. The increase in R&D expense was primarily due to an increase in contract manufacturing costs for ficlatuzumab and tivozanib, payments to Kyowa Hakko Kirin related to the up-front license payment received from Astellas, as well as an increase in personnel-related expenses mainly due to increased support for tivozanib development activities. These increases were partially offset by reimbursable amounts under the cost sharing provisions of AVEO’s collaboration agreement with Astellas.

General and administrative (G&A) expense for 2011 was $29.2 million compared with $14.8 million for 2010. The increase in G&A expense was primarily driven by non-recurring expenses for strategic, legal and financial advisors incurred in connection with AVEO’s collaboration agreement with Astellas, an increase in personnel-related expenses and expenses related to pre-commercialization activities for tivozanib.

Net income for 2011 was $30.6 million, or basic and diluted earnings per share of $0.77 and $0.74, respectively, compared with a net loss of $58.8 million, or basic and diluted loss per share of $2.30 for 2010.

AVEO ended 2011 with cash, cash equivalents and marketable securities of $275.4 million.

Completed top-line analysis of pivotal tivozanib Phase 3 trial, TIVO-1: Notably, in the fourth quarter, AVEO completed top-line analysis of TIVO-1, a global, randomized, Phase 3, superiority clinical trial evaluating the efficacy and safety of tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma (RCC). Top-line data were announced in January 2012 and showed that tivozanib successfully demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1. Key top-line findings from TIVO-1 include:

Tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 11.9 months compared to a median PFS of 9.1 months for sorafenib in the overall study population.

Tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 12.7 months compared to a median PFS of 9.1 months for sorafenib in the pre-specified subpopulation of patients who were treatment naïve (no prior systemic anti-cancer therapy); this subpopulation was approximately 70% of the total study population and reflects the first-line RCC setting in North America and Europe.

Tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well-established on-target and manageable effect of VEGFR inhibitors. The side effects commonly associated with other VEGFR inhibitors, such as diarrhea, fatigue and hand-foot syndrome, were notably low.

Initiated enrollment in tivozanib Phase 2 trial in patients with colorectal cancer, BATON-CRC: In December 2011, AVEO announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer (CRC). BATON-CRC, which is being led by AVEO’s collaborator Astellas, is the second trial to be initiated as part of the BATON (Biomarker Assessment of Tivozanib in ONcology) program, a series of clinical trials to assess tivozanib efficacy and biomarkers in solid tumors.

Entered into manufacturing agreement for ficlatuzumab with Boehringer Ingelheim: In December 2011, AVEO announced it entered into an agreement with Boehringer Ingelheim for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF inhibitory antibody that is currently being evaluated in a Phase 2 clinical trial as first-line therapy in combination with gefitinib versus gefitinib monotherapy in patients with non-small cell lung cancer. AVEO retains all rights to the development and commercialization of ficlatuzumab.

Leerink Swann 2012 Global Healthcare Conference, February 15-16, 2012 in New York City.

Citi 2012 Global Health Care Conference, February 27-29, 2012 in New York City.

2012 RBC Capital Markets’ Global Healthcare Conference, February 28-29, 2012 in New York City.

Cowen and Company 32^nd Annual Health Care Conference, March 5-7, 2012 in Boston, Mass.

Collaboration revenue

Operating expenses:

Research and development

General and administrative

Income (loss) from operations

Other income and expense:

Other income (expense), net

Interest expense

Interest income

Other expense, net

Net income (loss)

Basic net income (loss) per share

Net income (loss)

Weighted average number of common shares outstanding

Diluted net income (loss) per share

Net income (loss)

Weighted average number of common shares and dilutive common share equivalents outstanding

Current assets:

Cash and cash equivalents

Marketable securities

Accounts receivable

Prepaid expenses and other current assets

Total current assets

Marketable securities

Property and equipment, net

Other assets

Restricted cash

Total assets

Current liabilities:

Accounts payable

Accrued expenses

Loans payable, net of discount

Deferred revenue

Other liabilities

Deferred rent

Total current liabilities

Loans payable, net of current portion and discount

Deferred revenue, net of current portion

Deferred rent, net of current portion

Other liabilities

Stockholders’ equity:

Preferred Stock, $.001 par value: 5,000 shares authorized; no shares issued and outstanding at December 31, 2011 and 2010, respectively

Common stock, $.001 par value: 100,000 shares authorized; 43,254 and 35,604 shares issued and outstanding at December 31, 2011 and 2010, respectively

Additional paid-in capital

Accumulated other comprehensive loss

Accumulated deficit

Total stockholders’ equity

Total liabilities and stockholders’ equity